Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial
…of 6.8 years, accompanied by persisting antibodies to Epstein-Barr virus early antigens (titers greater than or equal to 1:40) or undetectable levels of antibodies to Epstein-Barr virus nuclear antigens (titers…